Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M

Mirum Pharmaceuticals, Inc.

2025-Q2 EPS reported -$0.42 revenue$239,370,000

Q2 global net product sales $127.8M, up 64% YoY from $77.9M.
LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).
FY 2025 revenue guidance raised to $490-510M from prior range.
Cash $321.7M; volixibat VISTAS topline expected Q2 2026.
MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.